Methods of treating rheumatoid arthritis with an anti-TNF-alpha antibodies and methotrexate
DC CAFC
First Claim
Patent Images
1. A method of treating an individual suffering from rheumatoid arthritis whose active disease is incompletely controlled despite already receiving methotrexate comprising adjunctively administering with methotrexate therapy a different composition comprising an anti-human tumor necrosis factor-α
- antibody or a human tumor necrosis factor-α
binding fragment thereof to the individual, wherein the anti-human tumor necrosis factor-α
antibody or fragment thereof (a) binds to an epitope on human tumor necrosis factor-α
, (b) inhibits binding of human tumor necrosis factor-α
to human tumor necrosis factor-α
cell surface receptors and (c) is administered at a dosage of 0.01-100 mg/kg, and wherein such administration reduces or eliminates signs and symptoms associated with rheumatoid arthritis.
4 Assignments
Litigations
0 Petitions
Reexamination
Accused Products
Abstract
Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn'"'"'s disease, and acute and chronic immune diseases associated with transplantation.
55 Citations
22 Claims
-
1. A method of treating an individual suffering from rheumatoid arthritis whose active disease is incompletely controlled despite already receiving methotrexate comprising adjunctively administering with methotrexate therapy a different composition comprising an anti-human tumor necrosis factor-α
- antibody or a human tumor necrosis factor-α
binding fragment thereof to the individual, wherein the anti-human tumor necrosis factor-α
antibody or fragment thereof (a) binds to an epitope on human tumor necrosis factor-α
, (b) inhibits binding of human tumor necrosis factor-α
to human tumor necrosis factor-α
cell surface receptors and (c) is administered at a dosage of 0.01-100 mg/kg, and wherein such administration reduces or eliminates signs and symptoms associated with rheumatoid arthritis. - View Dependent Claims (2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 20, 21, 22)
- antibody or a human tumor necrosis factor-α
-
3. A method for adjunctive treatment of an individual suffering from rheumatoid arthritis who still has active disease despite prior therapy with methotrexate and who is already being treated with methotrexate comprising administering a different composition comprising an anti-human tumor necrosis factor-α
- antibody or a human tumor necrosis factor-α
binding fragment thereof to the individual, wherein the anti-human tumor necrosis factor-α
antibody or fragment thereof is administered to the individual multiple times, each such administration (i) being separated by an interval of a week or weeks from the prior administration, and (ii) delivering 0.01-100 mg/kg of the anti-human tumor necrosis factor-α
antibody or fragment thereof and wherein such administration reduces or eliminates signs and symptoms associated with the rheumatoid arthritis. - View Dependent Claims (4)
- antibody or a human tumor necrosis factor-α
-
14. A method of treating an individual suffering from rheumatoid arthritis and already receiving methotrexate whose active disease is incompletely controlled comprising administering to the individual with methotrexate therapy a different composition comprising an anti-human tumor necrosis factor-α
- monoclonal antibody, wherein such administration reduces or eliminates signs and symptoms associated with the rheumatoid arthritis.
- View Dependent Claims (17, 18)
-
15. A method of treating an individual suffering from rheumatoid arthritis whose active disease is incompletely controlled by methotrexate comprising administering to the individual a different composition comprising an anti-human tumor necrosis factor antibody, wherein the anti-human tumor necrosis factor-α
- antibody is cA2and is administered repeatedly as adjunctive therapy to methotrexate therapy and wherein such administration reduces or eliminates signs and symptoms associated with the rheumatoid arthritis.
- View Dependent Claims (16)
-
19. A method of treating an individual suffering from active rheumatoid arthritis despite already receiving methotrexate comprising administering an anti-human tumor necrosis factor-α
- antibody to the individual, wherein the anti-human tumor necrosis factor-α
antibody binds specifically to human tumor necrosis factor-α
, and is administered in a different composition, in single or multiple doses, as adjunctive therapy to methotrexate therapy, wherein the methotrexate is administered in multiple doses and wherein such administration reduces or eliminates signs and symptoms associated with the arthritis.
- antibody to the individual, wherein the anti-human tumor necrosis factor-α
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeThe Kennedy Trust Rheumatology Research
-
Original AssigneeMathilda and Terence Kennedy Institute of Rheumatology Trust
-
InventorsMaini, Ravinder N., Feldmann, Marc
-
Primary Examiner(s)Gambel; Phillip
-
Application NumberUS11/225,631Publication NumberTime in Patent Office1,912 DaysField of SearchNoneUS Class Current424/145.1CPC Class CodesA61K 2039/505 comprising antibodiesA61K 2039/545 characterised by the dose, ...A61K 2300/00 Mixtures or combinations of...A61K 31/505 Pyrimidines; Hydrogenated p...A61K 31/519 ortho- or peri-condensed wi...A61K 38/1793 for cytokines; for lymphoki...A61K 39/395 Antibodies agglutinins A61K...A61K 39/39541 against normal tissues, cellsA61K 39/3955 against proteinaceous mater...A61K 45/06 Mixtures of active ingredie...A61P 1/00 Drugs for disorders of the ...A61P 19/02 for joint disorders, e.g. a...A61P 29/00 Non-central analgesic, anti...A61P 37/00 Drugs for immunological or ...A61P 37/06 Immunosuppressants, e.g. dr...C07K 16/241 Tumor Necrosis FactorsC07K 2317/24 containing regions, domains...C07K 2319/00 Fusion polypeptide
